netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 3: Respiratory system - Full Chapter
Chapter Links...
 Details...
03.01.02  Expand sub section  Antimuscarinic bronchodilators
Aclidinium (Eklira Genuair®)
View adult BNF View SPC online View childrens BNF
Formulary
Green

In line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

 
   
Ipratropium Bromide
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
   
Tiotropium (Spiriva® 18mcg inhalation)
View adult BNF View SPC online View childrens BNF
Formulary

Restricted Item Brown Traffic Light  Spiriva® 18mcg should not be initiated for new patients with COPD.

People whose treatment with Spiriva® 18mcg is not recommended in the Guidance on COPD Management in Primary care - Inhaled Therapies, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

APCO March 2017.

 
Link  MHRA Drug Safety Update: Safety studies of spiriva Respimat vs Handihaler
   
Tiotropium (Spiriva® Respimat 2.5mcg)
View adult BNF View SPC online View childrens BNF
Formulary

Green Traffic Light  In line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

Amber Traffic Light  For the treatment of asthma only as an add-on in adult patients who are currently treated with a combination of inhaled corticosteroids and long-acting beta2-agonists and who experienced one or more severe exacerbations in the previous year. See Maintenance Management of Asthma – Inhaled and Oral Therapies (adults).

APCO March 2015.

 
   
Umeclidinium (Incruse Ellipta®)
View adult BNF View SPC online View childrens BNF
Formulary
Green

In line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

 
   
 ....
 Non Formulary Items
Glycopyrronium  (Seebri breezhaler®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not recommended due to insufficient evidence.

APCO January 2013.

 
Tiotropium  (Braltus® 10mcg inhalation powder)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not recommended for use as device not in line with OCCG Guidance on COPD Management in Primary care - Inhaled Therapies and safety concerns regarding pre-metered dose.  

APCO July 2017.

Link  MHRA Drug Safety Update: Braltus (tiotropium)- risk of inhalation of capsule if placed in the mouthpiece of the inhaler
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary